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Abstract
Protein Tyrosine Phosphatase 1B (PTP1B) has been recognized as a promising therapeutic target for
treating obesity, diabetes, and certain cancers for over a decade. Previous drug design has focused on
inhibitors targeting the active site of PTP1B. However, this has not been successful because the active
site is positively charged and conserved among the protein tyrosine phosphatases. Therefore, it is
important to develop PTP1B inhibitors with alternative inhibitory strategies. Using computational studies
including molecular docking, molecular dynamics simulations, and binding free energy calculations, we
found that lupane triterpenes selectively inhibited PTP1B by targeting its more hydrophobic and less
conserved allosteric site. These findings were verified using two enzymatic assays. Furthermore, the cell
culture studies showed that lupeol and betulinic acid inhibited the PTP1B activity stimulated by TNFα in
neurons. Our study indicates that lupane triterpenes are selective PTP1B allosteric inhibitors with
significant potential for treating those diseases with elevated PTP1B activity.
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Selective binding modes and
allosteric inhibitory effects of
lupane triterpenes on protein
tyrosine phosphatase 1B
Tiantian Jin1, Haibo Yu2 & Xu-Feng Huang1
Protein Tyrosine Phosphatase 1B (PTP1B) has been recognized as a promising therapeutic target for
treating obesity, diabetes, and certain cancers for over a decade. Previous drug design has focused
on inhibitors targeting the active site of PTP1B. However, this has not been successful because the
active site is positively charged and conserved among the protein tyrosine phosphatases. Therefore, it
is important to develop PTP1B inhibitors with alternative inhibitory strategies. Using computational
studies including molecular docking, molecular dynamics simulations, and binding free energy
calculations, we found that lupane triterpenes selectively inhibited PTP1B by targeting its more
hydrophobic and less conserved allosteric site. These findings were verified using two enzymatic
assays. Furthermore, the cell culture studies showed that lupeol and betulinic acid inhibited the PTP1B
activity stimulated by TNFα in neurons. Our study indicates that lupane triterpenes are selective PTP1B
allosteric inhibitors with significant potential for treating those diseases with elevated PTP1B activity.
Protein Tyrosine Phosphatase 1B (PTP1B) is an intracellular protein which is widely expressed in the body
including the brain, liver, muscles, and adipose tissue, and which is up-regulated in obesity, type 2 diabetes and
breast cancer1–3. Obesity is a major health problem leading to various life-threatening diseases such as diabetes,
cardiovascular disease and certain cancers4. An elevated PTP1B level contributes to the development of obesity
and its related metabolic disorders5,6. Considerable efforts have been made towards new anti-obesity drug developments. PTP1B has been considered as a therapeutic target for treating obesity. Previous studies have shown
that inhibiting neuronal PTP1B in obese mice reduces fat deposition, improves energy expenditure and prevents
weight gain7,8.
However, there are some outstanding challenges in PTP1B-based small-molecule therapeutics. First, it is difficult to achieve inhibition selectivity against PTP1B by targeting the active site. PTP1B is a member of the Protein
Tyrosine Phosphatase (PTP) family, which contains more than 100 members. Most PTPs have a consensus active
loop signature (H/V)C(X)5R(S/T), where the cysteine (C) is a conserved active site that is essential for enzyme
catalysis9. Of particular interest, PTP1B shares a 74% identical sequence in its catalytic domain with T-cell protein
tyrosine phosphatase (TCPTP)10 and they have almost superimposable active sites. TCPTP has different biological functions and signalling pathways from PTP1B as demonstrated in mouse models11. Studies have shown
the regulatory functions of TCPTP on the immune system12. Homozygous TCPTP-deficient mice died at 3–5
weeks of age due to the haematopoietic defect caused by immune system damage11. Therefore, an effective PTP1B
inhibitor needs to have sufficient selectivity for PTP1B over TCPTP. Second, inhibitors targeting the intracellular
target PTP1B need to have satisfactory cellular penetration. Current PTP1B inhibitors are designed to bind to the
PTP1B active site, the phosphotyrosine (pTyr)-binding pocket, serving as competitive inhibitors to reduce PTP1B
activity13. These PTP1B inhibitors mimic pTyr and are negatively charged at a physiological pH. Consequently, it
is difficult for most PTP1B inhibitors to penetrate the cell membrane14.
Due to the challenges of the active site targeted inhibitors mentioned above, an alternative drug design
strategy has been proposed to develop inhibitors targeting the PTP1B allosteric site instead13. Recent X-ray
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Figure 1. The crystallography structure of PTP1B. PTP1B has an active site Cysteine 215 with surrounding
catalytic loop (a) and a previous identified allosteric site (b) which is surrounded by α 3 helix, α 6 helix and α 7
helix. During PTP1B activation, WPD loop (c) moves from the open position to the closed position.

crystallographic studies have revealed an allosteric transition in PTP1B accompanying its catalysis, which is situated about 20 Å away from the catalytic domain including active site Cys215 and catalytic loop consisting His214,
Ser216, Ala217, Gly218, Ile219, Gly220 and Arg22115,16 (Fig. 1a,b). The catalytic WPD loop (Trp179, Pro180,
and Asp181) and neighbouring residues can exist in two distinct conformations: “open” and “closed”17 (Fig. 1c).
In the open state, the WPD loop stands beside the active site to form an open binding site, which is accessible
for substrates. In contrast, in the closed state, the WPD loop closes over the binding site, forming a catalytically
competent state. Thus an allosteric inhibitor can be designed to prevent the movement of the WPD loop and
maintain the WPD loop in an open (inactive state)16. Unlike the active site of PTP1B, the allosteric site is not well
conserved among PTPs and is substantially less polar15. Thus targeting the allosteric site might offer a promising
approach to developing PTP1B inhibitors with both improved selectivity and bioavailability. The high-resolution
X-ray structures of PTP1B, in complex with three allosteric inhibitors, including compound 2 and compound
3 (Fig. 2), show that these inhibitors target the allosteric site formed by α 3, α 6 and α 716. Encouragingly, these
allosteric inhibitors show high potency in inhibiting PTP1B with selectivity over other PTPs16. Considering the
limited selective PTP1B inhibitors on trial18, allosteric inhibition becomes a promising strategy to discover selective PTP1B inhibitors19,20.
Recently, the lupane triterpenes, lupeol, lupenone, betulin and betulinic acid (Fig. 2), have been shown to
be potent PTP1B inhibitors in vitro21–23. Na et al. showed that lupeol can inhibit PTP1B with a high potency
(IC50 =  5.6 μ M), and acts as a non-competitive inhibitor of PTP1B21. Therefore lupeol might target a binding site
other than the active site of PTP1B. We propose the lupane triterpenes as potential PTP1B allosteric inhibitors
and aim to reveal their molecular inhibitory mechanisms. First, we performed molecular docking, molecular
dynamics simulations and binding affinity calculations to predict the allosteric binding site targeted by lupane
triterpenes and characterise the key interactions and residues involved in the binding. Second, we used enzymatic
assays to determine the inhibition selectivity of lupane triterpenes against PTP1B over TCPTP. We carried out
kinetic assays to confirm their allosteric binding modes. Finally, we examined the cellular activities of selected
lupane triterpenes for their ability to inhibit PTP1B activity in hypothalamic neurons. This combination of molecular modelling, enzymatic assays and cell culture studies has established lupane triterpenes as potent and selective
PTP1B inhibitors with significant potential for treating diseases with elevated PTP1B activity.

Methods

Homology modelling of PTP1B.

The PTP1B crystal structure (PDB id: 1T49) used in this study was
the open, inactive conformation containing 282 amino acids, in which the α 7 was not resolved (labelled as
PTP1B282). Considering that there was no crystal structure of PTP1B with α 7 available in the inactive state, and
also the important role of α 7 in allosteric inhibition, homology modelling with Modeller 9v8 was carried out to
construct the missing helix based on the active conformation of PTP1B (PDB id: 1PTY) (labelled as PTP1B299)24.
100 models were generated and the best model based on the DOPE energy was chosen and subjected to equilibrium molecular dynamics simulations (40 ns) to equilibrate and optimise the modelled structure (see Molecular
dynamics simulations).
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Figure 2. The formula of allosteric ligands used. Compounds 2 and 3 have been reported to be allosteric
inhibitors by Wiesmann et al.16. Four members of the lupane triterpenes are selected for this work.

Molecular docking.

Docking simulations were carried out with Autodock Vina (version 1.1.2)25. The
docking protocol was established by re-docking compound 2 to PTP1B282 as in the co-crystal structure16. The
protonation states of the titratable groups in PTP1B were assigned at pH 7.0 by PROPKA3.126. Docking was
performed sequentially in two steps. Initially, a box large enough to cover the whole protein (75 Å ×  60 Å ×  60 Å)
was used to detect potential binding pockets. Then, the second step involved localised docking with a smaller box
(22.5 Å ×  22.5 Å ×  22.5 Å) centred at the potential binding site of interest (e.g. the active site, the allosteric site, or
other site of interest identified from the blind docking procedure). In each focused docking study of lupane triterpenes targeting PTP1B282 or PTP1B299, 20 conformations of the complexes with the lowest binding affinities
were listed for further analysis and the best binding mode was selected to be the initial structure for the molecular
dynamics simulations. Multiple dockings, based on different snapshots sampled from equilibrium molecular
dynamics simulations (PTP1B282 and PTP1B299), were performed. Qualitatively, the identified populated binding poses are similar.

Molecular dynamics simulations. Molecular dynamics simulations were performed to study the stability

and flexibility of the PTP1B-lupane triterpenes complexes. 9 different systems were set up (Table S1). All of the
systems were solvated in a box of TIP3P water molecules, which extended about 12 Å from the surface of the
protein, and the systems were neutralised with counter ions of Na+. The salt (NaCl) concentration was set to
0.15 mol/L. Simulations were carried out using NAMD 2.927. The protein and the ligands were represented with
the non-polarisable CHARMM PARAM27 force field28 and the GAFF force field29, respectively. All of the systems
were simulated in periodic boundary conditions using the Langevin algorithm to maintain the temperature at
298.15 K, and the Langevin Piston Nose-Hoover method to keep the pressure constant at 1.0 bar. The electrostatic
interactions were calculated using the Particle Mesh Ewald (PME) method30. The van der Waal forces were treated
with a cut-off of 12 Å. All of the covalent bonds involving hydrogen were kept rigid using the Rattle algorithm and
time step set to 1.0 fs. In the equilibrium simulations of the homology modelling of PTP1B, a harmonic restraint
on the backbone atoms except α 7 was applied with a decreasing force constant from 64.0 to 1.0 kcal/mol/Å2 over
10 ns. The simulations were continued for 30 ns without any restraints. For the molecular dynamics simulations of
the docked complexes, a harmonic restraint on the backbone atoms was applied with a decreasing force constant
from 32.0 to 1.0 kcal/mol/Å2 over 3 ns followed by 20 or 100 ns equilibrium simulations (Table S1).

Binding free energy calculation. Free energy perturbation distributed replica-exchange molecular
dynamics (FEP/λ -REMD) was applied to calculate binding free energy31,32. The motivation to carry out computationally intensive absolute binding free energies is because the binding modes for lupeol and betulinic acid
predicted by docking and subsequently molecular dynamics simulations are rather different. This could be difficult for relative binding free energy calculations, which assume that their available conformational spaces are
significantly overlapped33. To be consistent with previous literature, we call the free energy difference between
the unbound ligand in the aqueous solution and the bound ligand in the binding pocket of the target protein as
the absolute binding free energies. The total free energy was decomposed into four terms, namely repulsive and
dispersive components of the Lennard-Jones potential according to the Weeks-Chandler-Anderson scheme, the
Scientific Reports | 6:20766 | DOI: 10.1038/srep20766
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electrostatic contribution, and the restraining potential. The ligand was decoupled from the environment in four
steps via four thermodynamic coupling parameters (λ ). No corrections have been applied to the potential electrostatic finite-size artefacts34,35. In order to speed up the convergence, each λ -staging FEP window was treated
as a replica and the λ -exchange occurred along the entire alchemical reaction path. This approach has been successfully used to study the interactions between glycoside hydrolases and polysaccharides36. Generally, for both
PTP1B-lupeol and the PTP1B-betulinic acid complex, the FEP/λ -REMD simulations started from a 100 ns equilibrated snapshot. A set of 64 replicas (36 repulsive, 12 dispersive, and 16 electrostatic) was applied in the simulations with an exchange frequency of one every 1,000 steps (1 ps). For each replica, a total of 1.0 ns simulations were
carried out in which the last 0.8 ns simulations were averaged to determine the ligand binding free energies. The
protein-ligand complexes included a positional translational restraint with a force constant of 10.0 kcal/mol/Å2.
The error analyses were estimated using four sequential simulations of 0.2 ns each.

Analysis. Trajectory snapshots were saved every picosecond (i.e. every 1,000 steps) and analysed using either
the the molecular visualisation program VMD 1.937 or CHARMM38.
Inhibiting TCPTP by pNPP phosphatase assay. The inhibition of TCPTP was determined by using the
EnzoLyte Colorimetric pNPP Protein Phosphatase Assay kit (Anaspec, San Jose, CA). The recombinant human
TCPTP protein (ab42575) was purchased from Abcam Inc (Cambridge, MA). Lupeol, betulin, and betulinic acid
were purchased from Sigma-Aldrich (Castle Hill, NSW). Lupenone was purchased from Faces Biochemical Co
Ltd (Wuhan, P R China). Briefly, TCPTP was incubated in different concentrations of compounds for 10 min in
assay buffer at 25 °C, and then the reaction was initiated by adding the pNPP reagent and stopped by NaOH after
30 min at 25 °C. All readings were calibrated on the negative control wells without enzymes. The TCPTP inhibition potency of the lupane triterpenes was determined by IC50, calculated using the GraphPad Prism 5 program
(GraphPad Software Inc, La Jolla, CA). In addition, both the inhibition of TCPTP and PTP1B (ab42572, Abcam
Inc, Cambridge, MA) were performed with the control drug compound 3 (Merck, Frenchs Forest, NSW), a
reported allosteric PTP1B inhibitor. The PTP1B assay process was the same as the TCPTP assay mentioned above.
PTP1B inhibition kinetics assay. The PTP1B-catalysed hydrolyses in the presence of betulin and betulinic
acid were assayed at 25 °C, and the pNPP Protein Phosphatase Assay kit is described above. The reaction mixture
consisted of six different concentrations of pNPP (1.0, 2.0, 4.0, 8.0, 16.0, and 20.0 mM) and was used as a PTP1B
substrate with different concentrations of lupeol, betulin, and betulinic acid. The Lupeol group was used as a
control group. The absorbance at 405 nm was detected by a spectraMAX 384 microplate spectrophotometer twice
every minute for a total of 15 min. Michaelis-Menten constant (Km) and maximum velocity (Vmax) of PTP1B were
determined via Lineweaver-Burk plots using the GraphPad Prism 5 program (GraphPad Software Inc, La Jolla,
CA).
Cell culture and reagents. Mouse hypothalamic cell line (mHypoE-46) neurons were grown in monolayer
in Dulbecco’s modified Eagle medium (DMEM) (Sigma D5796, Castle Hill, NSW) with 10% fetal bovine serum
(FBS) (SAFC Biosciences Inc, Lenexa, KS) and 1% penicillin/streptomycin. They were maintained at 37 °C with
5% CO2. Prior to treatment, the cell culture medium was replaced with DMEM containing 1% penicillin/streptomycin for 4 h. Murine TNFα was obtained from Sigma-Aldrich (Castle Hill, NSW). Lupeol and betulinic acid
were dissolved in Dimethyl sulfoxide (DMSO), then diluted in sterile water, and mixed with serum free cell
culture medium. The DMSO concentration was controlled below 0.15%. The final concentrations of lupeol and
betulinic acid in the cell culture medium were 28 μ M (5× of the IC50 value) and 7.5 μ M (5× of the IC50 value),
respectively.
Western blot analysis. The method was described in our previous study with modifications39, mHypoE-46

neurons were washed with ice-cold PBS and lysed in NP-40 lysis buffer (Invitrogen Australia Pty Ltd, Mulgrave,
VIC) containing a protease inhibitor cocktail, beta-glycerophosphate and phenylmethanesulfonyl fluoride
(PMSF) (Sigma, Castle Hill, NSW). Cell lysates were centrifuged at 14000 rpm for 10 min at 4 °C. The supernatants were collected and protein concentrations were determined using the DC assay (Bio-Rad Laboratories,
Gladesville, NSW) according to the manufacturer’s instructions. Equal amounts of protein (10 μg) were separated on 4–12% Bis-Tris gels (Bio-Rad Laboratories, Gladesville, NSW,) using SDS-PAGE. Following electrophoresis (120 V for 2 h), the proteins were transferred to polyvinylidene difluoride membranes (100 V for 1 h).
Membranes were blocked in 5% bovine serum albumin (BSA), followed by incubation with the primary antibodies PTP1B (sc-1718, 1:500, Santa Cruz Biotechnology Inc, Dallas, TX) in 1% BSA overnight at 4 °C. Following
washes (3 ×  5 min) in Tris Buffered Saline +0.1% Tween 20 (TBST), membranes were incubated with horseradish
peroxidase conjugated secondary antibodies for 1 h at 25 °C. Blots were visualised using enhanced chemiluminescence (ECL) detection reagents (Ge Healthcare, Rydalmere, NSW). The bands corresponding to the proteins of
interest were scanned and densitometrically analysed using the automatic imaging analysis system Quantity One
(Bio-Rad Laboratories, Gladesville, NSW). All quantitative analyses were normalised to β-actin.

Immunoprecipitation assay of PTP1B. Based on the instructions of the Pierce Classic IP Kit (#26146,
Thermo Fisher Scientific Inc, IL) with minor modifications40, PTP1B was immunoprecipitated using the 25 μg
PTP1B antibody (sc-1718, Santa Cruz Biotechnology Inc, Dallas, TX) for 12 h at 4 °C. Immune complexes were
isolated by adding the protein G-agarose, washed three times in the phosphatase assay buffer from the EnzoLyte
Colorimetric pNPP Protein Phosphatase Assay kit (Anaspec, San Jose, CA), and resuspended in the same buffer.
Samples were analysed for the phosphatase activity using the same pNPP assay kit mentioned above.
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Figure 3. Equilibrated structures of the homology model for PTP1B299. The snapshots sampled from the
molecular dynamics simulations at 10 ns (red), 15 ns (grey), 20 ns (orange), 25 ns (yellow), 30 ns (tan), 35 ns
(silver), and 40 ns (green), are superimposed with the homology model using Modeller (blue).

Statistical analysis.

Data from the western blot analysis and immunoprecipitation assays were analyzed
using the SPSS 19 statistical package (SPSS, Chicago, IL). One-way analysis of variance (ANOVA) was applied
followed by the post-hoc Tukey-Kramer honestly significant difference (HSD) test.

Results

Lupeol binds to PTP1B in the allosteric site. The homology model of PTP1B in the inactive state with
compound 2 (PTP1B299 w/Compound 2, see Fig. 2) was simulated for 50 ns: the first 10 ns with a harmonic
restraint on the backbone atoms of the resolved crystal structure while optimising the modelled α 7; and the
remaining 40 ns being free molecular dynamics simulations. The snapshots sampled during the simulations are
shown in Fig. 3. In general, the tertiary structures were stable for over 40 ns with the modelled α 7 having greater
flexibility. As expected for the relative short timescale of the free molecular dynamics simulations, no closure of
the active site was observed and PTP1B remained in the inactive state.
One of the remaining problems of allosteric inhibition is to characterise the binding modes of these inhibitors
and identify the key residues involved in the binding. In particular, the truncated form of PTP1B without α 7 is
four times less active, indicating the importance of α 7 in PTP1B inhibition16. In addition, X-ray structures have
revealed that in the presence of an allosteric inhibitor, α 7 is disordered and thus the molecular details of α 7 in
allosteric inhibition remain unclear16. To determine the role of α 7, molecular docking studies (blind and focused
docking) were performed for PTP1B in the presence of α 7 (PTP1B299) or absence of α 7 (PTP1B282). These
docking studies revealed similar binding modes for lupeol with the interactions for PTP1B299 being stronger. The
following discussions focus mainly on PTP1B299 and note the differences between PTP1B282 and PTP1B299.
α7 is involved in forming the allosteric binding site in PTP1B299. The blind docking studies revealed
that lupeol preferentially binds to the identified allosteric site16 (Table S2 and Figure S1a). Subsequently, we
obtained a more accurate picture of the binding modes from the focused docking at the allosteric site (Figure S1b).
The molecular dynamics simulations of the docked complex showed a stable trajectory with the backbone positional root-mean-square deviations (RMSDs) of the PTP1B backbone atoms being 1.0 – 1.5 Å. Throughout the
simulation, the WPD loop remained open, indicating that PTP1B was inactive and the timescale for the opening/
closure of the WPD loop was beyond the current simulation timescale41. Considering that the structure of lupeol
is mainly hydrophobic with only one polar hydroxyl group, it appears that hydrophobic interactions play a critical
role in binding (Fig. 4).
α7 helix strengthens the hydrophobic interactions between lupeol and PTP1B. The presence of α 7 creates a hydrophobic “tunnel”, which surrounds lupeol and provides stronger hydrophobic interactions (Fig. 4c). This results in
a tighter binding mode with the largest affinity of − 10.3 kcal/mol (Table S3), compared to − 7.7 kcal/mol (Table
S4) in the PTP1B282 allosteric site. The hydrophobic tunnel comprised 6 non-polar amino acids located within
5 Å around lupeol including Ala189, Leu192, Phe196, Phe280, Trp291 and Leu294 (Fig. 4c, Table S5), which was
significantly larger than the hydrophobic area formed by the two hydrophobic residues in PTP1B282 w/Lupeol
(Phe196 and Phe280, Fig. 4d). We compared the solvent accessible surface areas (SASA) for PTP1B binding with
lupeol (Table 1). Generally, reducing SASA increased the hydrophobic interactions. All of these six non-polar residues decreased SASAs in PTP1B299 w/Lupeol, indicating that a non-polar interaction was established between
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Figure 4. The top-ranked binding poses of lupeol to the allosteric site of PTP1B299 (a) and PTP1B282
(b). Detailed interactions revealed by the molecular dynamics simulations for lupeol and PTP1B are shown in
(c) and (d). The hydrophobic residues involved in the binding in PTP1B299 (Ala189, Leu192, Phe196, Phe280,
Trp291, and Leu294) are shown in Surf. The polar residue involved in the hydrogen bonding Gln288 is shown
in CPK (c). The hydrophobic residues involved in the binding in PTP1B282 (Phe196 and Phe280) are shown in
Surf while the polar residue involved in the hydrogen bonding in Asn193 is shown in CPK (d).
Ala189

Leu192

Phe196

Phe280

Trp291

Leu294

47.6

29.1

90.7

83.4

109.3

138.0

PTP1B299 w/Lupeol

7.9

0.3

25.9

64.2

5.5

105.1

PTP1B282 w/Lupeol

50.4

14.9

50.7

107.4

PTP1B299

Table 1. Changes in solvent accessible surface area (SASA) values upon lupane triterpenes to PTP1B. The
values are the non-polar residues in the PTP1B299, PTP1B299 w/Lupeol complex, and PTP1B282 w/Lupeol
complex over the trajectories of equilibrated simulations (in Å2).
lupeol and these hydrophobic residues (Table 1). In particular, Leu192, Phe196 and Trp291 had respective
100-fold, 4-fold and 20-fold decreases in SASAs when they interacted with lupeol. These residues contributed
significantly to the additional hydrophobic interactions. More importantly, individual mutations of Leu192Ala
and Phe196Ala have been reported to significantly reduce the inhibitory effect of an allosteric inhibitor targeting
the same binding pocket , indicating the prominent role of these residues in allosteric inhibition42. On the other
hand, the SASAs of hydrophobic residues in PTP1B299 w/Lupeol were significantly lower than in PTP1B282 w/
Lupeol (Table 1). This indicates that the existence of α7 led to a larger hydrophobic area to wrap around lupeol. In
addition, we compared root-mean-square fluctuations (RMSFs) for Cα atoms in PTP1B before and after lupeol
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Figure 5. Root-mean-square fluctuations (RMSF) per residue in the equilibrium molecular dynamics
simulations of PTP1B282, PTP1B282 w/Lupeol, PTP1B299, and PTP1B299 w/Lupeol. The key secondary
structure elements including catalytic domain, WPD loop and allosteric site composed by α 3, α 6 and α 7, have
been labelled along X-axis.

binding. Lupeol binding increased the fluctuations of α 7 (Fig. 5), which may lead to the disorder of α 7. Such
order to disorder transition upon binding has been proposed to play an important role in allosteric inhibition16.
Orientation of lupeol in the binding site changes due to the presence of α7. Notably, although lupeol binds to the
same site with or without α 7, its orientation changes (Fig. 4a,b). This change is likely due to the presence of α 7,
which changed the preferred hydrogen bonding formation at the binding site. In PTP1B299 w/Lupeol, the residue
Gln288 in α 7 formed a hydrogen bond with the hydroxyl group in lupeol (Fig. 4c). However, in PTP1B282 w/
Lupeol, Asn193 formed a hydrogen bond with lupeol (Fig. 4d). Nevertheless, docking simulations suggest that
both hydrophobic and hydrogen bonding interactions contributed to lupeol binding.

Lupane triterpenes are allosteric inhibitors for PTP1B. Lupane triterpenes share the same skeleton
structure with minor differences in their polar functional groups (Fig. 2). The key functional group of lupane triterpenes is a pentacyclic triterpene displaying a non-polar characteristic, which interacts with non-polar residues
in the allosteric site of PTP1B299. It is likely that the specific polar functional group of each lupane triterpene
determines the diversity of the binding modes and leads to different binding affinities targeting PTP1B. In addition to lupeol, we also subjected lupenone, betulin, and betulinic acid to molecular docking (Figures S2, S3 and S4,
Tables S2 and S3). To further elucidate the difference of binding modes within the lupane family, molecular
dynamic simulations were performed on these compounds (Table S1) and the top-ranked docked complexes were
confirmed to be stable over the duration of 100 ns (Figures S5 and 6).
PTP1B299w/Lupeol. α 7 enhanced the hydrophobic interactions, and created a strong hydrogen bond with
lupeol (Fig. 4c). The different rotamers of Gln288 in α 7 formed different hydrogen bonding patterns with lupeol,
with Gln288 acting as either a hydrogen bonding donor or acceptor to strengthen the interactions with lupeol.
The estimated occupancy was 73% between lupeol and Gln288 during the 100 ns simulations (Fig. 7).
PTP1B299 w/Lupenone. The polar functional group in lupenone was a carbonyl group that formed one hydrogen bond with Lys197 in the docked complex (Fig. 6d). There was a relatively low occupancy of 33% in the
molecular dynamics simulations (Fig. 7). In contrast, the hydrophobic interactions formed with the non-polar
residues Ala189, Leu192, Phe196, Phe280, Trp291, and Leu294 were maintained throughout the simulations
(Fig. 6d, Table S5).
PTP1B299 w/Betulin. Betulin had two hydroxyl groups that formed multiple hydrogen bonds in the docking
studies (Fig. 6e). The molecular dynamics simulations revealed the formation of three populated hydrogen bonds
between betulin and Asn193, Glu276, and Gln288. The occupancies for these hydrogen bonds were 41%, 29% and
22%, respectively (Fig. 7) with considerable fluctuations in the 100 ns simulations. The hydrophobic interactions
were stable and the residues involved in the binding included Ala189, Leu192, Phe196, Phe280, Trp291, and
Leu294 (Fig. 6e, Table S5).
PTP1B299 w/Betulinic acid. Betulinic acid contained two polar functional groups that formed three stable
hydrogen bonds (Fig. 6f). The carboxyl group was close to Glu276 to form one hydrogen bond with an occupancy
of 37%. Additionally, betulinic acid contained a hydroxyl group, which formed another two hydrogen bonds with
Gln288 (occupancy of 58%) and Lys292 (occupancy of 37%) in the 100 ns simulations (Fig. 7). Of the four lupane
triterpenes, betulinic acid formed the strongest polar interactions with PTP1B. Like the other lupane triterpenes,
the strong hydrophobic interactions involved in binding were with Ala189, Leu192, Phe196, Phe280, Trp291, and
Leu294 (Fig. 6f, Table S5).
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Figure 6. The top-ranked binding poses of lupenone (a), betulin (b), and betulinic acid (c) to the allosteric site
of PTP1B299. The detailed interactions revealed by the molecular dynamics simulations between the ligands
and PTP1B are shown in (d–f), respectively. The non-polar residues involved in the hydrophobic interactions
with the ligands are shown in Surf. The polar residues involved in hydrogen bonding are shown in CPK.

Binding affinities of Lupeol and Betulinic acid to PTP1B299. The absolute binding free energies of
lupeol and betulinic acid to PTP1B299 were calculated by FEP/λ -REMD. Table 2 lists the binding free energies
of the two ligands examined here together with the repulsive, dispersive, electrostatic, and restrained components. The free energy of solvation is also provided. Betulinic acid had a more favourable binding than lupeol
(− 10.6 kcal/mol vs − 12.2 kcal/mol, respectively). These binding affinities are comparable with those provided by
the scoring function in AutoDock Vina (Table S3). The relative binding free energy difference of −1.6 kcal/mol
compares favourably from the experimentally derived number based on IC50 values. Experimentally, IC50 is not
a direct indicator of binding affinities for non-competitive inhibitors, which however could be converted to each
other. According to the algorithm proposed by Cer et al.43. We estimated the constant of inhibition ki for lupeol
and betulinic acid and then calculated the binding free energies of lupeol and betulinic acid (− 7.5 kcal/mol vs
− 8.3 kcal/mol, respectively, Table S6). The current calculations overestimate the absolute binding free energies by
3.1 kcal/mol and 3.9 kcal/mol for lupeol and betulinic acid, respectively. However, the relative binding affinity of
− 0.8 kcal/mol was reproduced by binding free energy calculations reasonably well (− 1.6 kcal/mol). Such calculations provide confidence that in the future, relative binding free energy calculations will be applied to help the
optimisation of the lead compounds with similar binding modes.
We further examined the component contributions to the binding affinities. As expected, for both ligands,
the van der Waals interactions made the dominant contributions, because the allosteric site was characterised
of the hydrophobic interactions with the hydrophobic skeleton of lupane triterpenes. The difference of van der
Waals components between lupeol and betulinic acid to PTP1B299 was − 0.6 kcal/mol (Table 2, − 11.7 kcal/mol
vs − 12.3 kcal/mol). However, it is worth noting that betulinic acid had a slightly favourable contribution from
the electrostatic interactions compared to lupeol (Table 2). The difference of electrostatic interactions in lupeol
and betulinic acid was about − 1.0 kcal/mol (Table 2, 0.9 kcal/mol vs − 0.1 kcal/mol). Such component analyses
might provide useful information in future ligands optimisation process. For instance, the binding affinities might
be enhanced by increasing the hydrophilicities of the groups at R1 and R2 (Fig. 2), or the compounds solubility
be improved by strengthening hydrogen binding interactions by such groups. However, it is worth mentioning
that one has to be cautious as such free energy components are not a state function and component analyses are
pathway dependent44. Thus when using this information to in silico design new inhibitors, the (relative) binding
free energy will be verified with rigorous free energy calculations.
Lupane triterpenes selectively inhibit PTP1B activity over TCPTP. Allosteric inhibitors are selectively characterised by the inhibition effect. We have confirmed that lupane triterpenes are PTP1B allosteric
inhibitors using molecular docking and dynamics simulations. We have systematically testified the inhibitory
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Figure 7. The occupancy of the hydrogen bond in the 100 ns simulations of PTP1B299 w/Lupeol,
PTP1B299 w/Lupenone, PTP1B299 w/Betulin, and PTP1B299 w/Betulinic acid. A hydrogen bond is
assumed to exist if the donor-acceptor distance is smaller than 3.5 Å and the donor-hydrogen-acceptor is larger
than 135°. Both lupeol and lupenone perform only one hydrogen bond with PTP1B but the occupancy in lupeol
is much higher than lupenone. Both betulin and betulinic acid generate multiple hydrogen bonds with PTP1B.

ΔGbo
Lupeol

a

Betulinic acida

ΔGtotal

ΔGrep

ΔGdisp

ΔGelec

− 3.8 ±  0.4

43.7 ±  0.4 − 42.1 ±  0.2

− 9.2 ±  0.4

44.5 ±  0.3 − 43.3 ±  0.2 − 10.4 ±  0.3

ΔGrstr

− 5.4 ±  0.1

Lupeol− PTP1B299b

− 10.6 ±  0.6 − 14.4 ±  0.6 54.9 ±  0.5 − 65.0 ±  0.2

− 4.5 ±  0.2

0.2

Betulinic acid-PTP1B299b

− 12.2 ±  0.7 − 21.4 ±  0.7 56.0 ±  0.6 − 67.1 ±  0.2 − 10.5 ±  0.2

0.2

Table 2. Absolute binding free energies of lupeol and betulinic acid to PTP1B. The repulsive (Δ Grep),
dispersive (Δ Gdisp), electrostatic (Δ Gelec) and restraining (Δ Grstr) contributions sum up to the total in the
FEP/λ -REMD simulations31,32. The error is estimated on the four sequential simulations with each of 0.2 ns
for each replica. There are two separate free energy calculations, where in (a) a solvated ligand is decoupled
from the aqueous solution to vacuo, and in (b) a bound ligand is decoupled from the enzyme in solution. The
difference between values of (a) and (b) is the absolute binding free energy for a ligand to PTP1B (Δ Gbo).
effects of lupane triterpenes on PTP1B and TCPTP and demonstrated that lupane triterpenes specifically target
PTP1B. First we applied the control drug compound 3 (Fig. 2) to both the PTP1B and TCPTP enzymes to confirm the reliability of the enzymatic assay. The IC50 of compound 3 on PTP1B was 9.4 μ M (Fig. 8a), which was
similar to that of 8.0 μ M reported in the literature16. The IC50 of compound 3 on TCPTP was 62.7 μ M (Fig. 8b),
indicating that compound 3 had a 6.6-fold selectivity for PTP1B over TCPTP. The IC50 of lupane triterpenes for
TCPTP was determined and compared to the IC50 for PTP1B as reported in the literature21–23 (Table 3). The data
indicate that lupeol, lupenone, betulin and betulinic acid are modest but promising inhibitors for PTP1B with the
IC50 being 5.6, 13.7, 15.3, and 1.5 μ M, respectively. All of the lupane triterpenes had a weaker inhibitory effect on
TCPTP, being 126.1 (lupeol, Fig. 8c), 91.5 (lupenone, Fig. 8d), 118.7 (betulin, Fig. 8e), and 124.2 μ M (betulinic
acid, Fig. 8f), respectively. In particular, lupeol and betulinic acid had a 20-fold and 80-fold selectivity for PTP1B
over TCPTP, respectively.

Lupane triterpenes inhibit PTP1B activity in an allosteric manner.

Enzyme kinetic assays have
shown that lupeol and lupenone are non-competitive inhibitors for PTP1B, indicating that they target a binding site other than the active site, potentially the allosteric site21. We performed kinetic analysis of betulin and
betulinic acid, with lupeol as a control (Fig. 9a). The modes of inhibition by betulin and betulinic acid were
determined by applying the Lineweaver-Burk plot to 6 different pNPP and 4 different compound concentrations.
As shown in Fig. 9, both betulin and betulinic acid showed a decreased Vmax value, indicating that they were not
competitive inhibitors. Moreover, betulinic acid was a non-competitive inhibitor having a constant Km value
with a decreased Vmax value (Fig. 9b). Betulin displayed an altered Km value and a decreased Vmax value, classified
as mixed-type inhibition (Fig. 9a). None of lupane triterpenes were competitive inhibitors indicating that these
compounds target an allosteric binding site.

Lupane triterpenes attenuate PTP1B expression and activity in hypothalamic neurons.

Activation of PTP1B by TNFα in mHypoE-46 neurons. Neuronal PTP1B has a major role in obesity development5. The up-regulation of hypothalamic neuronal PTP1B expression induced by TNFα has been found in
animal models1,7,45. In this study, we applied TNFα to induce PTP1B expression and activity in a mouse hypothalamic cell line (mHypoE-46). TNFα (20 ng/ml) had a time-course effect on PTP1B which increased PTP1B
expression 1.75-fold (Figure S6), and PTP1B activity 1.5-fold (Fig. 10b) after 8 h treatment. We then investigated
the cellular activity of lupane triterpenes in inhibiting PTP1B expression and activity. Lupeol and betulinic acid
were chosen for the in vitro experiments as they showed strong potency and selectivity in inhibiting PTP1B in the
enzymatic assays (Table 3).
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Figure 8. The percentage inhibition of PTP1B (a) and TCPTP (b–f) activity. Compound 3 is used as a control
to validate the inhibition assay targeting PTP1B (a) and TCPTP (b). Four lupane triterpenes are tested for the
inhibition potency of TCPTP: (c) Lupeol; (d) Lupenone; (e) Betulin; and (f) Betulinic acid.

PTP1B (μM)

TCPTP (μM)

Fold changes

5.621

126.1

22

Lupenone

13.721

91.5

6

Betulin

15.323

118.7

7

1.522

124.2

81

Lupeol

Betulinic acid

Table 3. Inhibition potency of lupane triterpenes (IC50) targeting PTP1B and TCPTP. The data for PTP1B
are taken from refs 21–23.

Lupeol and betulinic acid inhibit cellular PTP1B activity. Lupeol (28 μ M, 5× the IC50 value) and betulinic
acid (7.5 μ M, 5× the IC50 value) were administrated to the mHypoE-46 cell line for 10 h after treatment of
TNFα for 8 h. The cells were collected for western blot and immunoprecipitation analysis. The Western blot
results showed that lupeol and betulinic acid slightly decreased PTP1B protein expression (Fig. 10a). However,
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Figure 9. PTP1B kinetics assay of lupeol, betulin, and betulinic acid indicated by Lineweaver-Burk plot.
(a) The concentrations of lupeol are 0 μM, 5 μM, 10 μM, and 20 μM, respectively. (b) The concentrations of betulin
are 0 μM, 7.5 μM, 15 μM, and 30 μM, respectively. (c) The concentrations of betulinic acid are 0 μM, 2 μM, 3 μM,
and 4 μM, respectively.
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Figure 10. Selected lupane triterpenes inhibit PTP1B protein expression and enzyme activity in
mHypoE-46 neurons. Lupane triterpenes slightly decrease TNFα -induced PTP1B protein expression (a), and
significantly inhibit PTP1B enzyme activity (b). The results shown are expressed as mean ±  SEM (n =  5 per
group). Significance is calculated by one-way ANOVA and the post-hoc Tukey-Kramer HSD test. *p <  0.05,
versus control (without TNFα and lupane triterpenes treatments).
immunoprecipitation revealed that PTP1B enzyme activity was significantly inhibited by 35% (Fig. 10b). This
indicates that lupeol and betulinic acid penetrated the cell membrane and reduced cellular PTP1B enzymatic
activity.

Discussion

There is compelling evidence that PTP1B is a promising therapeutic target for treating obesity and other diseases.
However, it is a major challenge to develop a potent and selective PTP1B inhibitor. Only a few selective PTP1B
inhibitors with acceptable pharmacological properties have been reported in the literature, such as TransTech
Pharma Inc TTP814, and Ohr Pharmaceutical Inc Trodusquemine (MSI-1436)42, which are in Phase II and
Phase I testing, respectively18. Recently, allosteric inhibition has become a promising alternative strategy to
develop selective PTP1B inhibitors. The current study firstly predicts that lupane triterpenes bind to the PTP1B
allosteric site by the application of molecular docking and molecular dynamics simulations. Enzymatic assays
and neuronal cell cultures were used to demonstrate that lupane triterpenes are potential selective and allosteric
inhibitors that target PTP1B. PTP1B allosteric inhibitor is featured by displaying a selective inhibitory effect on
PTP1B over TCPTP. In an addition to these results, we also performed blind docking of lupane triterpenes targeting TCPTP (Figure S7, Table S7) and compared the results to those targeting PTP1B (Figure S1a, S2a, S3a and
S4a). For each lupane triterpene, it is clear that only one pose among the top-ranked poses binds to the region
which is equivalent to the allosteric site in PTP1B (Table S7). Thus the less-conserved PTP1B allosteric site is an
ideal target for lupane triterpenes to inhibit PTP1B activity. This specificity may cause fewer side effects than the
PTP1B active site inhibitors.
Previous structural and biochemical studies have unveiled the important role of α7 as a regulatory helix in the
PTP1B conformational transition16. However, its mechanism remains unclear. Our results elucidate the contribution of α 7 to the allosteric binding mode. Firstly, α 7 is involved in the formation of PTP1B-ligand binding. The
presence of α 7 determines the orientation of lupeol (Fig. 4a,b) and RMSF data reveals a high fluctuation of α 7
due to the existence of lupeol (Fig. 5). Therefore α 7 directly interacts with lupeol to form the protein-ligand complex. Moreover, using blind and focused docking, we observed stronger binding affinities of lupeol in the presence
of α 7 (Table S3 and Table S4). SASA results indicate that the presence of α 7 results in increased hydrophobic
interactions as α 7 provides more non-polar residues (Table 1). Lupeol contains a non-polar pentacyclic structure,
which easily forms strong hydrophobic interactions with the hydrophobic “tunnel” formed by α 7. In addition,
experimental and computational studies on lupenone, betulin, and betulinic acid consolidate the role of α 7.
Lupane triterpenes are of great interest to traditional medicine46–48. Lupeol has been reported to be an
anti-diabetes agent49,50, an anti-cancer agent51, and an anti-inflammation agent46. Betulinic acid also shows
anti-obesity activity52, anti-HIV activity53, and anti-cancer activity53. However, the exact target of lupane triterpenes remains unclear. Our Western blot and immunoprecipitation results show that lupeol and betulinic acid
do not significantly decrease PTP1B protein expression in hypothalamic neurons (Fig. 10a). In contrast, PTP1B
enzyme activity is significantly inhibited (Fig. 10b). Thus lupeol and betulinic acid directly inhibit PTP1B enzyme
activity in vitro.
PTP1B is also involved in many diseases including cancer54, inflammation7, and diabetes55. Since lupane triterpenes directly target PTP1B activity, they are a potential treatment for several diseases. Betulinic acid shows
higher inhibition potency as its polar functional groups form stronger hydrogen bonding interactions than
lupeol, lupenone, and betulin (Fig. 7). Consistent with the IC50 data in table 3, the results from binding free
energy calculations showed that betulinic acid had a better inhibitory effect than lupeol. Their contributions of
van del waal interactions were similar, therefore the electrostatic interactions mainly contributed to the slightly
lower Δ Gbo for betulinic acid (Table 2). It is encouraging to see the relative consistency between experimental
results and computed data in our current work. More importantly, via investigating the structure of lupane triterpenes (Fig. 2), it is clear to notice that lupane triterpenes share a highly hydrophobic pentacyclic main structure
which lead to the similarity of van del waal interactions between lupeol and betulinic acid. On the other hand,
the structural difference between lupeol and betulinic acid lies in the R2 group, which plays a vital role strongly
increasing the inhibitory effect of betulinic acid. Since the non-polar pentacyclic structure of lupane triterpenes
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is the premise for binding to the less polar allosteric site, modifying the polar functional group is a pivotal way to
increase binding affinity and inhibition potency. R2 (Fig. 2) is regarded as an ideal site to be modified to introduce
the polar functional groups. However, such modifications need careful investigation since this will affect their
pharmacokinetic properties.

Conclusion

As an important negative regulator in controlling human energy homeostasis, PTP1B is an attractive drug target
for preventing and treating obesity and its associated metabolic syndromes. We establish computational modelling for lupane triterpenes binding to PTP1B, and demonstrate that lupane triterpenes function as allosteric inhibitors targeting PTP1B. Our future work will include detailed structural characterizations of the PTP1B-lupane
triterpene complex and the rational optimization of these compounds for better efficacy. Thus exploring lupane
triterpenes offers the opportunity to develop novel PTP1B allosteric inhibitors with high potency, selectivity, and
few side effects.
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